Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202457 | 0.95 | KMT2A (0.39) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL20215065 | 0.91 | HSD17B3 (0.47) | HSD17B3NOTUMKDM4EHTTSMN1; SMN2 | |
| SCHEMBL21366027 | 0.89 | KMT2A (0.36) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL20991257 | 0.89 | RIPK1 (0.41) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL21089788 | 0.87 | SMN1; SMN2 (0.34) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL18179935 | 0.87 | KMT2A (0.40) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL21366319 | 0.87 | HSD17B3 (0.35) | HSD17B3NOTUMKDM4EHTTSMN1; SMN2 | |
| SCHEMBL26616332 | 0.87 | SMN1; SMN2 (0.37) | KMT2AMEN1HSD17B3NOTUMKDM4E | |
| SCHEMBL19604395 | 0.87 | HSD17B3 (0.35) | HSD17B3NOTUMKDM4EHTTSMN1; SMN2 | |
| SCHEMBL22472682 | 0.87 | KDM4E (0.47) | HSD17B3NOTUMKDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2024-01-02 | — | — | US | disclosed |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2024-01-02 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230381284-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-11-30 | — | — | US | disclosed |
| US-20230381284-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-11-30 | — | — | US | disclosed |
| US-20230364199-A1 | IMPROVEMENT OF PHYSICAL AND MENTAL WELL-BEING OF PATIENTS WITH HYPOPARATHYROIDISM | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-11-16 | — | — | US | disclosed |
| US-11793861-B2 | PTH prodrugs | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-10-24 | — | — | US | disclosed |
| US-20230321198-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-10-12 | — | — | US | disclosed |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-09-19 | — | — | US | disclosed |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | KMT2A 2203/4885MEN1 4707/4885HSD17B3 4241/4885 |
| US-20230364199-A1 | IMPROVEMENT OF PHYSICAL AND MENTAL WELL-BEING OF PATIENTS WITH HYPOPARATHYROIDISM | PTH1R, CRH, PTMS | KMT2A 1763/4885MEN1 45/4885HSD17B3 623/4885 |
| US-11793861-B2 | PTH prodrugs | PTH1R, PTMS, PHPT1 | KMT2A 3758/4885MEN1 84/4885HSD17B3 671/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | KMT2A 2203/4885MEN1 4707/4885HSD17B3 4241/4885 |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | KMT2A 4427/4885MEN1 40/4885HSD17B3 505/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | KMT2A 1139/4885MEN1 1055/4885HSD17B3 2336/4885 |
| US-20230381284-A1 | Controlled-Release PTH Compound | PTH1R, CALCA, CALCB | KMT2A 4146/4885MEN1 25/4885HSD17B3 840/4885 |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | KMT2A 697/4885MEN1 1830/4885HSD17B3 4679/4885 |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | KMT2A 4427/4885MEN1 40/4885HSD17B3 505/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | KMT2A 2203/4885MEN1 4707/4885HSD17B3 4241/4885 |
| US-20230321198-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCB, AVPR2 | KMT2A 4023/4885MEN1 39/4885HSD17B3 657/4885 |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | KMT2A 2811/4885MEN1 846/4885HSD17B3 2776/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | KMT2A 1978/4885MEN1 4727/4885HSD17B3 4166/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | KMT2A 1283/4885MEN1 3766/4885HSD17B3 4524/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | KMT2A 2277/4885MEN1 1297/4885HSD17B3 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.